Home
R StocksTrader Stocks Live Prices
Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc.

Available to platforms

Conatus Pharmaceuticals Inc. (Ticker: CNAT) was a biotechnology company focused on developing treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and liver fibrosis. Its lead product candidate, emricasan, aimed to reduce liver inflammation and improve liver function. In 2020, Conatus merged with Histogen Inc., transitioning its resources and focus to regenerative medicine and aesthetic dermatology.

Conatus Pharmaceuticals Inc. - CNAT stocks live chart

Analyze price movements of Conatus Pharmaceuticals Inc. online with R StocksTrader’s advanced stock charts. There's no need to manually refresh the chart as quotes are updated automatically in real-time. View both the current and previous CNAT quotes – including the latest bid at 0.53 USD and ask at 0.56 USD – and get all the necessary information for adding Conatus Pharmaceuticals Inc. to your investment portfolio.

With R StocksTrader, you can invest in Conatus Pharmaceuticals Inc. and explore real stocks and CFDs on other prominent American and European companies. Stocks, Indices, Metals – over 12,000 assets are available for trading on our web terminal. Explore the dynamic price movements of popular assets, like Conatus Pharmaceuticals Inc., and expand your trading opportunities by investing in new instruments in 2025.

Risk Warning: Past performance of CNAT does not predict future returns.

FAQ

Open a trading account at RoboForex, decide on the number of assets to buy and then place an order for Conatus Pharmaceuticals Inc. (CNAT).

You can trade Conatus Pharmaceuticals Inc. (CNAT) on the R StocksTrader platform.

You can trade online Conatus Pharmaceuticals Inc. (CNAT) on Prime, ECN, Pro, or R StocksTrader accounts.

All financial charts